60 Charlotte Street
London W1P 2AX
United Kingdom
Phone: +44 (0) 20 7074 4600

Malcolm Weir, CEO
Privately Held


Founded in 1998, Inpharmatica Ltd. develops and markets information-based solutions for drug discovery and has developed the information source, Biopendium, which relates gene and protein sequences to their structure and function. Inpharmatica is focused on proteomic analysis, which it then applies to drug discovery and for the identification of targets.

In addition, the company has a second product, Chemtatica, a database that comes as a module for Biopendium for matching small molecules to protein binding sites.


The company has collaborations with Arrow Therapeutics to discover antimicrobial drugs and with Pfizer Inc., which was the first partner to gain access to Biopendium. In addition, Genentech Inc. has become a subscriber and it has a collaboration with Celera Genomics to develop a Celera Edition Biopendium. The Celera collaboration will marry Biopendium with Celera’s proprietary mammalian sequences and all public domain sequences to create a resource of integrated sequence, structural and functional information.

Other partners include Serono SA for the discovery of novel protein therapeutics.